Sarcopenia Market Expected to Experience Major Growth by 2034, According to DelveInsight | TNF Pharma, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross\n\nThe Key Sarcopenia Companies in the market include - TNF Pharmaceuticals, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross, Mirscience Therapeutics, Turn Biotechnologies, NMD PHARMA, ImmunoForge, Dong Wha PHARM, and others. DelveInsight’s \"Sarcopenia Market Insights, Epidemiology, and Market Forecast-2034\" report offers an in-depth understanding of the Sarcopenia, historical and forecasted epidemiology as well as the Sarcopenia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.\n\nSome of the key facts of the Sarcopenia Market Report: The Sarcopenia market size was valued ~USD 2,000 million in 2024 and is anticipated to grow with a significant CAGR during the study period (2020-2034). In 2025, the Sarcopenia market size in the US was the largest among the 7MM, valued at around USD ~1,500 million, with further growth anticipated by 2034.\n\nIn April 2025, TNF Pharmaceuticals, Inc. announced that Mitchell Glass, M.D., President and Chief Medical Officer of TNF, delivered a platform presentation on the abstract titled \"Isomyosamine for the Treatment of Sarcopenia in Older Adults\" at the British Geriatrics Society (BGS) Spring Meeting 2025, which took place from April 9–11 in Belfast, Ireland, and online.\n\nIn December 2024, The US FDA awarded Fast Track Designation (FTD) to LPCN 1148 for the treatment of sarcopenia in patients with decompensated cirrhosis.\n\nIn December 2024, Epirium Bio, Inc. (Epirium) announced that the US Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for MF-300, a novel, orally administered 15-hydroxyprostaglandin dehydrogenase (15-PGDH) enzyme inhibitor being developed to treat sarcopenia, which is age-related muscle weakness.\n\nIn December 2024, Lipocine announced that the US Food and Drug Administration (FDA) has awarded Fast Track Designation to LPCN1148 for the treatment of sarcopenia in patients suffering from decompensated cirrhosis.\n\nKey companies developing therapies for sarcopenia include TNF Pharmaceuticals with MYMD-1/Isomyosamine, Biophytis with Sarconeos, and Lipocine with LPCN 1148. Additionally, several companies are working on early-stage sarcopenia treatments, such as ImmunoForge (Froniglutide), Rejuvenate Biomed (RJx-01), Keros Therapeutics (KER-065), and BPGbio (BPM 31510), along with others advancing their candidates through various stages of clinical development.\n\nIn 2024, the total number of diagnosed prevalent cases of sarcopenia across the 7MM was approximately 19,836,200, with projections indicating a rise throughout the study period (2020–2034).\n\nIn 2024, the UK had the highest number of diagnosed prevalent cases of sarcopenia among the EU4 and the UK, followed by Germany, while Spain reported the lowest number of cases.\n\nIn the US, sarcopenia cases are categorized by age groups: 65–69 years, 70–79 years, and 80 years and older. In 2024, the 65–69 age group had the highest number of cases, estimated at approximately 4,520,200.\n\nIn Japan, the estimated number of sarcopenia cases was around 5,225,100 in 2024.\n\nKey Sarcopenia Companies: TNF Pharmaceuticals, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross, Mirscience Therapeutics, Turn Biotechnologies, NMD PHARMA, ImmunoForge, Dong Wha PHARM, and others\n\nKey Sarcopenia Therapies: MYMD-1/Isomyosamine, LPCN 1148, Sarconeos (BIO101), Froniglutide (PF-1801), RJx-01, KER-065, BPM 31510 (ubidecarenone), OC514, MT29, TRN-005, NMDP-05, PF1807, DW1030, and others\n\nThe Sarcopenia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Sarcopenia pipeline products will significantly revolutionize the Sarcopenia market dynamics.\n\nSarcopenia Overview\nSarcopenia is a condition characterized by the gradual loss of muscle mass, strength, and function, typically associated with aging. It can lead to physical frailty, reduced mobility, and an increased risk of falls and fractures. Sarcopenia is often diagnosed through a combination of muscle mass measurements and assessments of strength or physical performance. It can be influenced by factors such as inactivity, poor nutrition, chronic illness, and hormonal changes. Early detection and management through exercise, diet, and, in some cases, medication, can help mitigate its effects.\n\nSarcopenia Epidemiology\nThe epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.\n\nSarcopenia Epidemiology Segmentation:\nThe Sarcopenia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:\nTotal Prevalence of Sarcopenia\nPrevalent Cases of Sarcopenia by severity\nGender-specific Prevalence of Sarcopenia\nDiagnosed Cases of Episodic and Chronic Sarcopenia\n\nSarcopenia Drugs Uptake and Pipeline Development Activities\nThe drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Sarcopenia market or expected to get launched during the study period. The analysis covers Sarcopenia market uptake by drugs, patient uptake by therapies, and sales of each drug.\nMoreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.\n\nThe report also covers the Sarcopenia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.\n\nSarcopenia Therapies and Key Companies\nMYMD-1/Isomyosamine: TNF Pharmaceuticals\nLPCN 1148: Lipocine\nSarconeos (BIO101): Biophytis\nFroniglutide (PF-1801): ImmunoForge\nRJx-01: Rejuvenate Biomed\nKER-065: Keros Therapeutics\nBPM 31510 (ubidecarenone): BPGbio\nOC514: Oncocross\nMT29: Mirscience Therapeutics\nTRN-005: Turn Biotechnologies\nNMDP-05: NMD PHARMA\nPF1807: ImmunoForge\nDW1030: Dong Wha PHARM\n\nDiscover more about therapies set to grab major Sarcopenia market share @ Sarcopenia Treatment Landscape\n\nSarcopenia Market Strengths\nLifestyle modifications, including exercise and proper nutrition, have shown efficacy in preventing and managing sarcopenia.\n\nSarcopenia Market Opportunities\nImproved integration of sarcopenia screening and management into routine healthcare practices can enhance early detection and intervention.\n\nScope of the Sarcopenia Market Report\nStudy Period: 2020–2034\nCoverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]\n\nKey Sarcopenia Companies: TNF Pharmaceuticals, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross, Mirscience Therapeutics, Turn Biotechnologies, NMD PHARMA, ImmunoForge, Dong Wha PHARM, and others\n\nKey Sarcopenia Therapies: MYMD-1/Isomyosamine, LPCN 1148, Sarconeos (BIO101), Froniglutide (PF-1801), RJx-01, KER-065, BPM 31510 (ubidecarenone), OC514, MT29, TRN-005, NMDP-05, PF1807, DW1030, and others\n\nSarcopenia Therapeutic Assessment: Sarcopenia current marketed and Sarcopenia emerging therapies\n\nSarcopenia Market Dynamics: Sarcopenia market drivers and Sarcopenia market barriers\n\nCompetitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies\n\nSarcopenia Unmet Needs, KOL’s views, Analyst’s views, Sarcopenia Market Access and Reimbursement \n\nTo know more about Sarcopenia companies working in the treatment market, visit @ Sarcopenia Clinical Trials and Therapeutic Assessment\n\nTable of Contents \n1. Sarcopenia Market Report Introduction\n2. Executive Summary for Sarcopenia\n3. SWOT analysis of Sarcopenia\n4. Sarcopenia Patient Share (%) Overview at a Glance\n5. Sarcopenia Market Overview at a Glance\n6. Sarcopenia Disease Background and Overview\n7. Sarcopenia Epidemiology and Patient Population\n8. Country-Specific Patient Population of Sarcopenia\n9. Sarcopenia Current Treatment and Medical Practices\n10. Sarcopenia Unmet Needs\n11. Sarcopenia Emerging Therapies\n12. Sarcopenia Market Outlook\n13. Country-Wise Sarcopenia Market Analysis (2020–2034)\n14. Sarcopenia Market Access and Reimbursement of Therapies\n15. Sarcopenia Market Drivers\n16. Sarcopenia Market Barriers\n17. Sarcopenia Appendix\n18. Sarcopenia Report Methodology\n19. DelveInsight Capabilities\n20. Disclaimer\n21. About DelveInsight\n\nAbout DelveInsight \nDelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.\n\nIt also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Sarcopenia Market Expected to Experience Major Growth by 2034, According to DelveInsight | TNF Pharma, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross

The sarcopenia market is projected to grow significantly by 2034, with a 2024 market size of ~USD 2,000 million. Key companies like TNF Pharmaceuticals, Lipocine, and Biophytis are developing therapies, including FDA Fast Track Designations for LPCN 1148 and MF-300. The market is segmented across the 7MM (US, EU4, UK, Japan) with varying prevalence rates and therapeutic pipelines.